Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
21 juli, 22:05
21 juli, 22:05
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
PR Newswire
CARLSBAD, Calif., July 21, 2025
CARLSBAD, Calif. , July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live Call Series on July 25 , 2025.
Details of the event are below:
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. TYRA-300's planned clinical development includes three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn .
Contact:
Amy Conrad
aconrad@tyra.bio
SOURCE Tyra Biosciences
21 juli, 22:05
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
PR Newswire
CARLSBAD, Calif., July 21, 2025
CARLSBAD, Calif. , July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live Call Series on July 25 , 2025.
Details of the event are below:
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. TYRA-300's planned clinical development includes three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn .
Contact:
Amy Conrad
aconrad@tyra.bio
SOURCE Tyra Biosciences
ECB
Analyser
Rapportperioden
Kryptovalutor
ECB
Analyser
Rapportperioden
Kryptovalutor
1 DAG %
Senast
Börsen idag
Igår, 17:47
Positivt på Stockholmsbörsen – Astra Zeneca lyfter efter positiva studieresultat
Integrum
Igår, 14:50
Budet på Integrum: Rekordhög premie
OMX Stockholm 30
1 DAG %
Senast
2 600,22